TauRx’s recent Rights Issue over-subscribed

Jul 05 - 2010 07:11 AM
TauRx’s recent Rights Issue exercise which closed on 2 July 2010 was over-subscribed by 3.52%. TauRx would like to thank our shareholders for their encouragement and strong support. Shareholders will be receiving the new share certificates via registered mail shortly.
Read more

Announcement: TauRx Rights Issue closure extends to 2 July 2010

Jul 02 - 2010 05:45 AM
TauRx has extended a Rights Issue which was initially scheduled to close on 29 June 2010
Read more

RSC Chapter: Role of Tau Aggregation Inhibitor Therapy in AD

Jul 01 - 2010 07:34 AM
TauRx has a new publication reviewing the role of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease.
Read more

TauRx enters collaborative R&D agreement with Bayer Schering Pharma

Jun 04 - 2010 01:45 AM
WisTa Laboratories Ltd.(a wholly owned subsidiary of TauRx Pharmaceuticals) has entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany that could redefine the way Alzheimer's disease and related disorders are currently being diagnosed and treated.
Read more

TauRx to Present at Jefferies 2010 Global Life Sciences Conference

Jun 02 - 2010 01:35 AM
Professor Claude Wischik, Co-founder and Executive Chairman of TauRx, will present at the Jefferies 2010 Global Life Sciences Conference in New York on June 9th, 2010.
Read more